<![CDATA[OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026]]>

Advertisement Commentary|Articles|May 8, 2026 OncLive Polls Reveal Picks for Top Lung Cancer Abstracts at ASCO 2026 Author(s)Caroline Seymour Fact checked by: Courtney Flaherty Listen0:00 / 0:00 Lung cancer experts rank key abstracts of interest from the upcoming ASCO Annual Meeting on OncLive’s social media. Advertisement As the 2026 ASCO Annual Meeting approaches, excitement is building across the lung cancer community for data that could redefine standards of care in both non–small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). From long-term targeted therapy follow-up to emerging immunotherapy and cell therapy strategies, this year’s meeting in Chicago promises to spotlight advances across multiple disease settings. To determine which abstracts have garnered the most interest, OncLive® conducted social media polls across LinkedIn and X. Poll: What will your focus be in lung cancer at the 2026 ASCO Annual Meeting?Oncogene-driven NSCLCAdjuvant therapy in NSCLC1L squamous NSCLCES-SCLCAmong 30 respondents on LinkedIn, oncogene-driven NSCLC emerged as the leading area of interest heading into the meeting, receiving 60% of the vote. Adjuvant therapy in NSCLC, frontline squamous NSCLC, and extensive-stage SCLC (ES-SCLC) each garnered 13% of responses.Conversely, among 6 respondents on X, oncogene-driven NSCLC emerged as the most anticipated focus area, receiving 50% of the vote. Frontline squamous NSCLC followed with 33% of responses, while ES-SCLC accounted for 17%. Adjuvant therapy in NSCLC did not receive any votes.Poll: What lung cancer abstract(s) will have your attention at the 2026 ASCO Annual Meeting?LBA8500/8515/8502LBA3/8000LBA4LBA8005When clinicians were asked to identify the single late-breaking abstract they were most looking forward to at ASCO, one LinkedIn respondent selected abstract(s) LBA3/8000, accounting for 100% of responses in that poll. On X, one respondent identified abstract LBA4 as the most anticipated presentation, also representing 100% of the vote.Based on these results, OncLive pooled a list of the most closely followed lung cancer abstracts being presented at the 2026 ASCO Annual Meeting. Read on for more insights on each study.Top Presentations to Watch at the 2026 ASCO Annual MeetingHR+ and HER2+ Breast CancerTriple-Negative Breast CancerLung CancerAbstract LBA8500: Sunvozertinib monotherapy versus platinum-based chemotherapy as first-line treatment for advanced NSCLC with EGFR exon20ins: Primary analysis of a multinational phase 3 randomized study (WU-KONG28)Presentation time: May 29, 1:00-1:12 PM CTLocation: Hall D2Oncogene-driven disease will be highlighted by the phase 3 WU-KONG28 trial (NCT05668988), which compares sunvozertinib (Zegfrovy) with platinum-based chemotherapy in patients with locally advanced or metastatic EGFR exon 20 insertion–positive NSCLC. Non-classical EGFR mutations remain challenging to manage due to limited targeted treatment options and biologic heterogeneity. Investigators are especially interested in whether sunvozertinib can improve efficacy while opening the door for future combination approaches in this molecular subgroup.Abstract 8515: Tremelimumab (T) + durvalumab (D) + chemotherapy (CT) vs pembrolizumab (P) + CT in 1L non-squamous (NSQ) metastatic NSCLC (mNSCLC) with STK11, KEAP1, and/or KRAS mutations (mut): Interim analysis (IA) of the phase 2b TRITON studyPresentation time: May 30, 1:45-1:51 PM CTLocation: Hall D2Another closely watched study is the phase 2b TRITON trial (NCT06008093), evaluating tremelimumab-actl (Imjudo) plus durvalumab (Imfinzi) and chemotherapy vs pembrolizumab (Keytruda) plus chemotherapy in metastatic nonsquamous NSCLC with STK11, KEAP1, and/or KRAS mutations. These molecular subsets have historically been associated with resistance to immunotherapy, making them a major unmet need in thoracic oncology. The interim analysis could help clarify whether dual checkpoint blockade strategies offer meaningful advantages in this difficult-to-treat population.Abstract 8502: Lorlatinib vs crizotinib as first-line treatment for advanced ALK+ non-small cell lung cancer: 7-year update from the phase 3 CROWN studyPresentation time: May 29, 2:00-2:12 PM CTLocation: Hall D2One of the most anticipated presentations is the 7-year update from the phase 3 CROWN trial (NCT03052608) comparing lorlatinib (Lorbrena) with crizotinib (Xalkori) in frontline ALK-positive NSCLC. Earlier updates from the study demonstrated unprecedented progression-free survival and strong central nervous system protection, helping establish lorlatinib as a preferred first-line option for many patients. Investigators and clinicians alike are eager to see whether the durability of benefit continues at the 7-year mark and how the long-term safety profile evolves.Abstract 8000: Randomized phase III study of nivolumab after surgery and adjuvant chemotherapy in NSCLC (ECOG-ACRIN EA5142, ALCHEMIST)Presentation time: June 1, 1:15-1:27 PM CTLocation: Hall D1Adjuvant immunotherapy will remain a major discussion point with results from the ECOG-ACRIN EA5142 ALCHEMIST study (NCT02595944). This randomized phase 3 trial is examining nivolumab (Opdivo) following surgery and adjuvant chemotherapy in patients with stage IB to IIIA NSCLC. The findings are particularly important, as many patients still undergo surgery before referral for neoadjuvant treatment, leaving room for effective postoperative strategies.Abstract LBA3: Event-free survival with adjuvant selpercatinib in stage IB-IIIA RET fusion–positive NSCLC: Primary results of the phase 3 LIBRETTO-432 trialPresentation time: May 31, 2:13-2:25 PM CLocation: Hall B1The phase 3 LIBRETTO-432 trial (NCT04819100) will also command significant attention with its evaluation of adjuvant selpercatinib (Retevmo) in stage IB to IIIA RET fusion–positive NSCLC. Experts believe positive findings could establish a new standard of care for patients with resected RET-driven disease. The presentation also reflects the broader momentum toward bringing precision medicine into earlier-stage lung cancer settings to reduce recurrence risk and improve long-term survival.Abstract LBA4: Ivonescimab plus chemotherapy versus tislelizumab plus chemotherapy in previously untreated advanced squamous non–small cell lung cancer: Overall survival results of the phase 3 HARMONi-6 trialPresentation time: May 31, 2:47-2:59 PM CTLocation: Hall B1In advanced squamous NSCLC, the phase 3 HARMONi-6 study (NCT05840016) will present overall survival (OS) findings for ivonescimab plus chemotherapy vs tislelizumab-jsgr (Tevimbra) plus chemotherapy in the frontline setting. Clinicians are eager for new therapeutic strategies in squamous histology, where progress has often lagged behind nonsquamous disease. The results may provide insight into whether novel combination approaches can further improve outcomes for patients with metastatic squamous NSCLC.Abstract LBA8005: Concurrent thoracic radiotherapy (TRT), platinum/etoposide chemotherapy, and durvalumab immunotherapy in extensive-stage (ES) small cell lung cancer (SCLC): A phase III trialPresentation time: June 1, 3:03-3:15 PM CTLocation: Hall D1The phase 3 TRIPLEX trial (NCT05223647) is evaluating concurrent thoracic radiotherapy (TRT) combined with platinum/etoposide chemotherapy and durvalumab (Imfinzi) in patients with ES-SCLC. The trial explores whether adding TRT to the current immunotherapy-based standard of care can further improve outcomes such as OS and disease control in this aggressive cancer subtype. These findings may help define a new treatment strategy for ES-SCLC and could influence future clinical practice guidelines.Want to learn more about why these abstracts are generating excitement? Check out this preview article featuring exclusive expert insights and visit our conference coverage page for daily updates on these presentations and more throughout the meeting. NewsletterStay up to date on the most recent and practice-changing oncology dataSubscribe Now! Advertisement Related ContentAdvertisementPoll Results Highlight Breast Cancer Abstracts of Interest at ASCO 2026ByAshling Wahner May 8th 2026First-Line Danvatirsen Plus Pembrolizumab Fails to Improve Response Rates in Metastatic HNSCCByAshling Wahner May 8th 2026Mentorship Is Key to Advance the Next Generation of Oncology ResearchersByKyle Doherty May 7th 2026Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts WarnByKyle Doherty May 7th 2026Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic CancerByCourtney FlahertyMay 7th 2026 Latest CMEVideoProactive Adverse Event Management for HER2+ BTC TreatmentsRahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCOView moreMultimediaCommunity Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for MelanomaYana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR View moreVirtual EventWisconsin Association of Hematology and Oncology1 Session is Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Empire State Hematology & Oncology SocietySeth A. Wander, MD, PhD; Girish Kunapareddy, MDView moreVirtual EventArkansas Association of Cancer Professionals2 Sessions are Available!View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | South Carolina Oncology SocietySeth A. Wander, MD, PhD; Kit Lu, MDView moreVideo19th Annual New York GU Cancers Congress®Maha Hussain, MD, FACP, FASCO; Daniel P. Petrylak, MDView moreIn-Person + Virtual EventGo to PER in ChicagoMay 29-31, 2026View moreVideoCommunity Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Tennessee Oncology Practice SocietySeth A. Wander, MD, PhD; Kamel Abou Hussein, MDView moreVirtual EventKansas Society of Clinical Oncology1 Session is Available!View moreVideoA Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCRView moreVideoEvolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular TestingEileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPHView moreVideoCases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoTumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLCBalazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MDView moreVideoMedical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic ApproachesRami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MDView moreVideoPER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging StrategiesJonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhDView moreVideoMedical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted TherapiesVinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MSView moreVideoMedical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple MyelomaC. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MDView moreVideoMedical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 DysregulationRebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhDView moreVideoCases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical InsightsGail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHSView moreVideoMedical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast CancerWilliam J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhDView moreVideoGI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal CancerJohn H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MDView moreVideoBreast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer TreatmentJoyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCOView moreMultimediaEstablishing the Rationale for ADC and ICI Combinations in TNBCVirginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCOView moreMultimediaBreaking Down the Rationale for Targeting TROP2 in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaDissecting Clinical Trial and Real-World Data for ADCs in TNBCFilipa Lynce, MD; Rita Nanda, MDView moreMultimediaEvaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MDView moreAudioBreaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MSView moreVideoOptimizing Treatment for Biliary Tract CancersGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreVideoCross-Disease Integration of Immunotherapy InnovationsGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreAudioPractical Considerations and Future Directions for New Treatment Strategies in SCLCRahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhDView moreMultimediaExpert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DScView moreVideoBroadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular CarcinomaGhassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhDView moreMultimediaPER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – NursingAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCOView moreMultimediaExpert Roundtable and Panel Discussions: Current and Future Landscape of TNBCAditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCOView moreVideoShow Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast CancerAna C. Garrido-Castro, MD; Pedram Razavi, MD, PhDView moreAudioNavigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New OptionsRahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhDView moreVideoMedical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk AssessmentJason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MDView moreMultimediaReady for Radioligand Therapy? Patient Selection and Sequencing SimplifiedJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaWorking Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary CareJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaBURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate CancerJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaImaging Matters: Decoding PSMA PET for Better Decision-MakingJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreMultimediaRadioligand Therapy 101: The Science Behind the StrategyJeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCOView moreVideo Advances in Managing EGFR-Mutant NSCLC: Applying Evidence Across the Disease ContinuumTina Cascone, MD, PhD; Christina Baik, MD, MPH; David Planchard, MD, PhDView moreMultimediaCommunity Practice Connections™: Enhancing Melanoma Outcomes With Intratumoral Oncolytic Immunotherapy–Strategies for the Multidisciplinary TeamYana G. Najjar, MD; Sapna Patel, MDView moreVideoA New Era of Targeted Therapy for Advanced NSCLC: Exploring Future Directions for Bispecific Antibodies and ADCsSandip Patel, MD, FASCO; Myung-Ju Ahn, MD; Giannis Mountzios, MD, MSc, PhD; Zofia Piotrowska, MD, MHSView moreVideoNavigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVOSriniVas R. Sadda, MD, FARVO; Mark R. Barakat, MD, FASRS; David A. Eichenbaum, MD, FASRSView moreVideoEnhancing Prostate Cancer Outcomes – The Role of PSMA and Targeted Treatment StrategiesAna Kiess, MD, PhD; Erin Grady, MD, CCD, FACNM, FSNMMI; Himanshu Nagar, MD, MS; Scott T. Tagawa, MD, MS, FASCO, FACPView moreVideo(CME Track) Antibody–Drug Conjugates in Oncology: The Essentials of AE Management for Better Patient OutcomesMichelle L. Taylor, ANP-BC; Emely Alfaro, DNP, RN, CNS, OCN; Paige Griffith, CRNP; Beth Sandy, MSN, CRNP, FAPOView more Advertisement Advertisement Trending on OncLive1Daraxonrasib Monotherapy Elicits Meaningful Responses in Previously Treated, RAS-Mutated Pancreatic Cancer2ASCO 2026 TNBC Deep Dive: Breast Cancer Experts Preview Practice-Informing Studies3FDA Completes Type A Meeting Following CRL for Tabelecleucel in EBV+ R/R Post-Transplant Lymphoproliferative Disease4Women With Bladder Cancer Face Diagnostic Delays as Symptoms Mimic UTIs, Experts Warn5Mentorship Is Key to Advance the Next Generation of Oncology Researchers